Physician profile
Katherine Vandervest
NPI 1336295963
$1,032.06
in general payments reported to CMS, 2019-2025
13 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2021: $12.60 · 2022: $13.43 · 2023: $496 · 2024: $234 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $258.28 | 2023 | 2nd Gen Centrimag Primary Console |
| Genentech USA, INC. | $147.37 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $121.36 | 2023 | Giapreza |
| Livanova USA, INC. | $116.05 | 2023 | Hemolung Cartridge Kit |
| Atricure, INC. | $64.67 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $55.34 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $53.70 | 2024-2025 | Fasenra |
| Vifor Pharma, INC. | $51.54 | 2024-2025 | Zemaira, Veltassa |
| Insmed, INC. | $51.46 | 2024-2025 | Arikayce |
| Glaxosmithkline, LLC. | $44.36 | 2024-2025 | Nucala |
| Genzyme Corporation | $34.80 | 2025 | |
| Grifols USA, LLC | $20.53 | 2025 | Prolastin-C Liquid |
| Medtronic, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Vandervest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.